HomeBUSINESS
BUSINESS

Mochida to Market Janssen’s Anticancer Agent Doxil in Japan
(Nov.22.2017)

Mochida Pharmaceutical said on November 20 that it has entered into an agreement with Janssen Pharmaceutical for the marketing of the partner’s anticancer agent Doxil Injection 20 mg (doxorubicin) in Japan. Under the pact, Mochida will be responsible for the information provisioning to medical institutions and the distribution of the product from January 2018 ...
(LOG IN FOR FULL STORY)